Overview
On 27 July 2010, orphan designation (EU/3/10/756) was granted by the European Commission to Altacor Ltd, United Kingdom, for tranilast for the prevention of scarring post glaucoma filtration surgery.
The sponsorship was transferred to Voisin Consulting S.A.R.L., France in November 2019.
In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.
Key facts
Active substance |
Tranilast
|
Intended use |
Prevention of scarring post glaucoma filtration surgery
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/10/756
|
Date of designation |
27/07/2010
|
Sponsor |
Voisin Consulting Life Sciences |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: